4//SEC Filing
Aggarwal Gaurav 4
Accession 0001213900-23-056885
CIK 0001766140other
Filed
Jul 12, 8:00 PM ET
Accepted
Jul 13, 8:42 PM ET
Size
18.9 KB
Accession
0001213900-23-056885
Insider Transaction Report
Form 4
Aggarwal Gaurav
Director
Transactions
- Conversion
Series A-1 Preferred Stock
2023-07-11$1000.00/sh−8,077$8,077,000→ 0 total(indirect: By Vivo Opportunity Fund Holdings, L.P.)Exercise: $0.49→ Common Stock (59,961,729 underlying) - Conversion
Tranche A Warrants (right to buy)
2023-07-11+12,802,388→ 12,802,388 total(indirect: By Vivo Opportunity Fund Holdings, L.P.)Exercise: $0.54→ Series A-3 Preferred Stock (12,802,388 underlying) - Conversion
Common Stock
2023-07-11+3,470,152→ 3,470,152 total(indirect: By Vivo Opportunity Fund Holdings, L.P.) - Conversion
Series A-2 Preferred Stock
2023-07-11+13,429,000→ 13,429,000 total(indirect: By Vivo Opportunity Fund Holdings, L.P.)→ Common Stock (13,429,000 underlying) - Conversion
Tranche B Warrants (right to buy)
2023-07-11+11,638,534→ 11,638,534 total(indirect: By Vivo Opportunity Fund Holdings, L.P.)Exercise: $0.59→ Series A-4 Preferred Stock (11,638,534 underlying) - Conversion
Tranche C Warrants (right to buy)
2023-07-11+18,621,655→ 18,621,655 total(indirect: By Vivo Opportunity Fund Holdings, L.P.)Exercise: $0.74→ Series A-5 Preferred Stock (18,621,655 underlying)
Footnotes (4)
- [F1]On July 11, 2023, the 8,077 shares of Series A-1 Preferred Stock then held by Vivo Opportunity Fund Holdings, L.P. automatically converted into (i) 3,470,152 shares of Common Stock, (ii) 13,429,000 shares of Series A-2 Preferred Stock, (iii) Tranche A Warrants to purchase 12,802,388 shares of Series A-3 Preferred Stock, (iv) Tranche B Warrants to purchase 11,638,534 shares of Series A-4 Preferred Stock and (v) Tranche C Warrants to purchase 18,621,655 shares of Series A-5 Preferred Stock. The shares of Series A-1 Preferred Stock had no expiration date.
- [F2]Vivo Opportunity Fund Holdings, L.P. is the record holder of the securities. The Reporting Person is a managing member of Vivo Opportunity, LLC, which is the general partner of Vivo Opportunity Fund Holdings, L.P. The Reporting Person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.
- [F3]Each of the Series A-2 Preferred Stock, Series A-3 Preferred Stock, Series A-4 Preferred Stock and Series A-5 Preferred Stock (collectively, the "Preferred Stock") is convertible into Common Stock on a one-for-one basis; however, the Preferred Stock is subject to blocking provisions which preclude such shares from being converted if such conversion would result in the holder obtaining greater than 9.99% of the Issuer's voting securities. The shares of Preferred Stock have no expiration date.
- [F4]The Tranche A Warrants, Tranche B Warrants and Tranche C Warrants are immediately exercisable for shares of Series A-3 Preferred Stock, Series A-4 Preferred Stock and Series A-5 Preferred Stock, respectively, and will each expire upon the Issuer's satisfaction of certain milestones.
Documents
Issuer
Unicycive Therapeutics, Inc.
CIK 0001766140
Entity typeother
Related Parties
1- filerCIK 0001551965
Filing Metadata
- Form type
- 4
- Filed
- Jul 12, 8:00 PM ET
- Accepted
- Jul 13, 8:42 PM ET
- Size
- 18.9 KB